<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of screening and diagnosis of heart disease in patients on dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of screening and diagnosis of heart disease in patients on dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of screening and diagnosis of heart disease in patients on dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher deFilippi, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William L Henrich, MD, MACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry A Borlaug, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiovascular disease is an important cause of morbidity and mortality in patients undergoing maintenance dialysis.</p><p>This topic provides an overview of screening and diagnosis of heart disease in patients on dialysis and includes discussion of the diagnosis of heart failure (HF) and asymptomatic left ventricular (LV) dysfunction in this patient population.</p><p>The management of heart disease in patients receiving maintenance dialysis is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>HF. (See  <a class="medical medical_review" href="/d/html/1961.html" rel="external">"Management of heart failure in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation. (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Chronic kidney disease'</a>.)</p><p></p><p class="headingAnchor" id="H499857860"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Ventricular-vascular remodeling and stiffening contribute to cardiovascular disease in patients on dialysis. Cardiac findings that are common in patients with end-stage kidney disease (ESKD) on dialysis include LV hypertrophy (LVH), diffuse myocardial fibrosis, and hemodialysis-induced myocardial stunning [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular hypertrophy </strong>– LVH is common among patients with ESKD with a reported prevalence of 75 percent [<a href="#rid2">2-4</a>]. LVH is a major risk factor for cardiovascular morbidity and mortality in patients with ESKD [<a href="#rid5">5</a>]. Among those who have LVH, two-thirds die from HF or sudden death, while one-third die from a noncardiovascular event. Worsening of LVH is a strong predictor of sudden death [<a href="#rid6">6</a>]. LVH is associated with increased QT interval and dispersal [<a href="#rid2">2</a>]. Both concentric and eccentric patterns of LVH  (<a class="graphic graphic_figure graphicRef87847" href="/d/graphic/87847.html" rel="external">figure 1</a>) are associated with risk of all-cause mortality among patients on dialysis [<a href="#rid7">7,8</a>]. Patients with eccentric LVH may be at higher risk of sudden death than patients with concentric LVH [<a href="#rid9">9,10</a>]. LVH is also associated with LV diastolic dysfunction, and diastolic dysfunction is also observed in some patients on dialysis without LVH [<a href="#rid7">7</a>]. LV systolic dysfunction is less common than LV diastolic dysfunction. Right ventricular (RV) dysfunction has also been observed in patients on dialysis [<a href="#rid11">11,12</a>]. LV diastolic or systolic dysfunction may progress to cause HF [<a href="#rid13">13</a>]. Ventricular stiffening related to LVH can also make the patient more vulnerable to episodes of hypotension during dialysis.</p><p></p><p class="bulletIndent1">Among patients on dialysis, the major risk factors for LVH are hypertension (particularly systolic blood pressure) and increasing age [<a href="#rid14">14,15</a>]. Chronic volume overload, anemia, Klotho deficiency, increased arterial stiffness with associated loss of aortic distensibility, and possibly an increase in cardiac index induced by the arteriovenous fistula created for hemodialysis access may also contribute. Elevated levels of fibroblast growth factor (FGF) 23 seen with decreased phosphorus renal clearance may directly contribute to an increase in LV mass independent of hypertension [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/1925.html" rel="external">"Cardiovascular and renal effects of anemia in chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial fibrosis</strong> – Cardiovascular magnetic resonance (CMR) imaging studies have suggested that diffuse myocardial fibrosis is common among patients with ESKD, even in the presence of a normal LV ejection fraction (LVEF), and is associated with LVH [<a href="#rid17">17-19</a>]. A pattern consistent with diffuse fibrosis or infiltration is distinct from a pattern of focal subendocardial fibrosis (likely caused by myocardial infarction) and a pattern of midwall fibrosis or infiltration [<a href="#rid19">19</a>]. Extensive fibrosis has also been identified on biopsy. As an example, endocardial biopsies were performed in a study of 40 patients with ESKD with dilated cardiomyopathy without coronary artery disease and in a control group of 50 patients not on dialysis with idiopathic dilated cardiomyopathy [<a href="#rid20">20</a>]. Severe myocyte hypertrophy and extensive fibrosis were characteristic of the dialysis group. Patients not on dialysis had a similar proportion of fibrosis but, overall, a much smaller proportion of severely hypertrophic myocytes (8 versus 45 percent in patients on dialysis). In the patients on dialysis, increasing fibrosis correlated with a decreased survival rate. CMR spectroscopy in patients with ESKD has identified altered myocardial metabolism with less efficient use of high-energy phosphates [<a href="#rid17">17,21</a>]. (See  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial stunning due to dialysis</strong> – Hemodialysis-induced myocardial stunning is common (eg, prevalences of 27 and 64 percent [<a href="#rid22">22,23</a>]) and is associated with reduced survival rates [<a href="#rid22">22,23</a>]. Hemodialysis-induced myocardial stunning is defined as hemodialysis-induced segmental LV dysfunction in the absence of known heart disease; however, the presence of coronary artery disease has not been excluded in studies of this condition. In support of an ischemic mechanism unrelated to coronary artery disease are observations of similar intradialytic cardiac stunning in 11 of 12 participants in a pediatric population (ages 2 to 17 years) [<a href="#rid24">24</a>]. At one-year follow-up, some patients with hemodialysis-induced myocardial stunning develop worsening LV systolic function with fixed (persistent) regional wall motion abnormalities [<a href="#rid22">22,25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uremic toxins</strong> – The retention of a wide variety of solutes in patients with impaired kidney function may adversely affect cardiac structure and function [<a href="#rid1">1</a>]. For example, high phosphate levels can directly damage endothelial cells and are associated with cardiovascular disease among patients on dialysis [<a href="#rid26">26,27</a>]. Compounds such as indoxyl sulfate and asymmetric dimethylarginine (ADMA) induce oxidative stress in vivo [<a href="#rid28">28-30</a>] and are associated with increased mortality and adverse cardiovascular events among patients with advanced chronic kidney disease [<a href="#rid31">31-33</a>]. Uremic retention solutes are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1916.html" rel="external">"Uremic toxins"</a>.)</p><p></p><p class="headingAnchor" id="H1655100648"><span class="h1">PREVALENCE AND PROGNOSIS</span></p><p class="headingAnchor" id="H3445401798"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Cardiovascular events account for over 40 percent of deaths of known etiology in end-stage kidney disease (ESKD) patients  (<a class="graphic graphic_figure graphicRef101338" href="/d/graphic/101338.html" rel="external">figure 2</a>) [<a href="#rid34">34</a>]. In general, patients with even mild chronic kidney disease have a greater burden of incident cardiovascular disease compared with similar age controls [<a href="#rid35">35,36</a>]. The specific causes of cardiovascular death are the same as in the general population and include ischemic causes, such as coronary heart disease, and nonischemic causes, such as cardiomyopathy, arrhythmias, and valvular heart disease. With declining renal function, there is a progressive shift from ischemic to nonischemic etiologies of cardiac death  (<a class="graphic graphic_figure graphicRef101342" href="/d/graphic/101342.html" rel="external">figure 3</a>), particularly sudden death in the absence of evidence of an acute myocardial infarction (AMI). (See  <a class="medical medical_review" href="/d/html/1922.html" rel="external">"Evaluation of sudden cardiac arrest and sudden cardiac death in patients on dialysis"</a>.)</p><p>Cardiovascular disease is also an important source of morbidity as the annual probability of hospital admission for HF and/or AMI for ESKD patients is greater than 20 percent, with a three- to fivefold greater probability of an admission for HF versus an AMI  (<a class="graphic graphic_figure graphicRef101340" href="/d/graphic/101340.html" rel="external">figure 4</a> and <a class="graphic graphic_figure graphicRef101341" href="/d/graphic/101341.html" rel="external">figure 5</a>) [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis"</a>.)</p><p>There are differences in the risk of HF and sudden death between patient groups treated with differing dialysis modalities, with a 34 percent lower rate of HF in patients on peritoneal versus hemodialysis. Furthermore, patients who receive peritoneal dialysis have a markedly lower sudden death rate than patients who receive hemodialysis (2 versus 7 percent) in the 12 months following the initiation of dialysis. This is counterbalanced by a higher unadjusted death rate in patients who receive peritoneal dialysis once diagnosed with HF or a myocardial infarction [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1278685072"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>HF is more common among patients on dialysis compared with the general population. In an analysis of the United States Renal Data System (USRDS) database in 2018, 43 percent of all patients on dialysis had prevalent HF (17 percent HF with reduced ejection fraction, 14 percent HF with preserved ejection fraction, and 12 percent undifferentiated HF) [<a href="#rid37">37</a>]. By comparison, the prevalence of HF in persons without ESKD is approximately 2.1 percent [<a href="#rid38">38</a>].</p><p>The presence of HF independently predicts early mortality in patients on dialysis, as it does in other patients [<a href="#rid39">39-43</a>]. In an analysis of data from the USRDS database, long-term survival was evaluated among 310,456 patients on hemodialysis with a first hospital admission for HF, fluid overload, or pulmonary edema [<a href="#rid43">43</a>]. Five-year survival was only 12.5, 20.2, and 21.3 percent for these three groups, respectively. Increasing clinical severity of HF, as determined by the New York Heart Association (NYHA) classification, is also associated with increased mortality in patients with ESKD [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/3501.html" rel="external">"Prognosis of heart failure"</a>.)</p><p>Causes and risk factors for HF in patients on dialysis are discussed below. (See <a class="local">'Causes and risk factors'</a> below.)</p><p class="headingAnchor" id="H2415117163"><span class="h2">Coronary heart disease</span><span class="headingEndMark"> — </span>The prevalence of coronary heart disease in patients on dialysis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a>.)</p><p class="headingAnchor" id="H902720211"><span class="h2">Valvular heart disease</span><span class="headingEndMark"> — </span>The prevalence of valvular heart disease in patients on dialysis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H2935846007"><span class="h2">Arrhythmias</span><span class="headingEndMark"> — </span>The prevalence of atrial fibrillation and risk of sudden cardiac arrest in patients on dialysis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1922.html" rel="external">"Evaluation of sudden cardiac arrest and sudden cardiac death in patients on dialysis"</a> and  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Chronic kidney disease'</a>.)</p><p class="headingAnchor" id="H1697497848"><span class="h1">SCREENING AND DIAGNOSIS OF HEART DISEASE</span></p><p class="headingAnchor" id="H2669824293"><span class="h2">Approach to screening and diagnosis</span><span class="headingEndMark"> — </span>As described above, heart disease is highly prevalent among patients on dialysis, and cardiac disease impacts prognosis and management (including dialysis therapies). Thus, as recommended in the 2005 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for cardiovascular disease in patients on dialysis, we suggest that patients receiving dialysis undergo screening for heart disease risk factors. In the absence of symptoms of coronary artery disease (CAD), we do not recommend diagnostic testing for CAD unless the patient is under evaluation for kidney transplant [<a href="#rid44">44-46</a>]. In each patient on dialysis, screening is performed to determine the need for additional testing for coronary heart disease, valvular heart disease, ventricular dysfunction, and arrhythmia. Screening of asymptomatic patients is performed in addition to standard diagnostic evaluation of patients with symptoms and signs of heart disease.</p><p>Screening includes the following components [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment for any symptoms or signs of heart disease. (See <a class="local">'Clinical manifestations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for traditional cardiovascular and uremia-related cardiovascular risk factors including diabetes, hypertension, dyslipidemia, smoking, physical activity, anemia, albuminuria, arterial stiffness/vascular calcification, serum phosphorus/parathyroid hormone level, inflammation (C-reactive protein [CRP]), and intradialytic hypotension. Of note, limited data are available on the effects of correction of modifiable traditional risk factors in patients with stage IV or greater chronic kidney disease, making specific recommendations challenging [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 12-lead electrocardiogram (ECG; at initiation of dialysis and annually) to identify signs of coronary heart disease and arrhythmia and is also helpful to serve as a baseline for comparison.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Doppler transthoracic echocardiogram once the patient is at dry weight early after initiation of dialysis (eg, during the first one to three months). Echocardiography is repeated every three years, as clinically appropriate given the patient's clinical condition. Approximately 87 percent of patients initiating dialysis will have abnormalities on echocardiography [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">The following are key echocardiographic features in patients with end-stage kidney disease (ESKD):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LV dimensions and wall thickness (to assess LV hypertrophy [LVH] and geometry)  (<a class="graphic graphic_figure graphicRef87847" href="/d/graphic/87847.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LV systolic function (LVEF) (see  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function", section on 'Echocardiography'</a>), which has implications for risk of coronary heart disease as well as risk of HF. (See <a class="local">'For coronary heart disease'</a> below and <a class="local">'For ventricular dysfunction'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LV diastolic function. (See  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a> and <a class="local">'For ventricular dysfunction'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessment of valve appearance and function. (See <a class="local">'For valvular heart disease'</a> below and  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Estimation of right atrial pressure and pulmonary artery systolic pressure, when possible. (See  <a class="medical medical_review" href="/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart", section on 'Hemodynamics'</a>.)</p><p></p><p>A referral to a cardiologist is suggested in the following settings: suspected HF, suspected coronary heart disease, suspected moderate or greater valve stenosis or regurgitation, new or unexplained pulmonary hypertension (pulmonary artery systolic pressure &gt;35 mmHg), or new-onset arrhythmias (eg, incident atrial fibrillation, marked bradycardia, or ventricular tachycardia).</p><p class="headingAnchor" id="H3557570307"><span class="h2">For coronary heart disease</span><span class="headingEndMark"> — </span>Additional testing to screen for coronary heart disease may be performed in selected patients on dialysis, including those with LVEF &lt;40 percent as well as in selected potential kidney transplant recipients. Additional criteria for stress testing and considerations in choosing a screening test are discussed separately. (See  <a class="medical medical_review" href="/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Coronary artery disease'</a> and  <a class="medical medical_review" href="/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)", section on 'Evaluation at dialysis initiation'</a>.)</p><p>While screening is performed for asymptomatic patients, diagnostic evaluation is performed for patients who develop symptoms of coronary heart disease, and monitoring is performed for patients with known coronary heart disease who have undergone coronary artery bypass graft surgery. (See  <a class="medical medical_review" href="/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)", section on 'Evaluation of symptomatic patients'</a>.)</p><p class="headingAnchor" id="H443355255"><span class="h2">For valvular heart disease</span><span class="headingEndMark"> — </span>Valvular heart disease should be assessed during the screening clinical evaluation and Doppler echocardiography (at baseline dry weight during the first one to three months and repeated every three years). Echocardiography enables assessment of valve appearance, motion, function, pulmonary pressures, as well as changes in ventricular size and function associated with valve disease. (See  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease", section on 'Evaluation'</a>.)</p><p>For asymptomatic patients on dialysis found to have valvular heart disease, recommendations for monitoring are similar to those for the general population except for greater frequency of follow-up for aortic stenosis. Cardiac calcification, including aortic valve calcification, occurs at an accelerated rate in patients on dialysis, and the rate of aortic stenosis progression is greater than that observed in the general population. (See  <a class="medical medical_review" href="/d/html/8117.html" rel="external">"Medical management of asymptomatic aortic stenosis in adults", section on 'Serial evaluation'</a> and  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease", section on 'Aortic stenosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients on dialysis with moderate aortic stenosis, annual echocardiography is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on dialysis with severe aortic stenosis, echocardiography is recommended every six months.</p><p></p><p>In addition, patients who develop signs and symptoms of valvular heart disease should undergo timely diagnostic evaluation including echocardiography. Clinical manifestations and diagnosis of valve disease in patients with ESKD are discussed separately. (See  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H413676551"><span class="h2">For ventricular dysfunction</span><span class="headingEndMark"> — </span>Ventricular dysfunction (eg, LV diastolic and/or systolic dysfunction) and LV remodeling (eg, LVH) should be assessed during the screening clinical evaluation and echocardiography performed at clinically determined dry weight as a baseline early after initiation of dialysis (eg, during the first one to three months) and repeated every three years. Most patients are volume overloaded at the time of initiation of dialysis, and it can take weeks to achieve relative euvolemia. In addition, some small studies have suggested that adjustment of the dry weight targets for patients who receive hemodialysis by echocardiography assessment of inferior vena cava size may improve blood pressure control and the quality of life [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a> and  <a class="medical medical_review" href="/d/html/1961.html" rel="external">"Management of heart failure in patients on dialysis", section on 'Dialysis prescription'</a>.)</p><p>In addition, patients who are being evaluated for kidney transplant generally undergo cardiac evaluation. (See  <a class="medical medical_review" href="/d/html/7333.html" rel="external">"Kidney transplantation in adults: The kidney transplant waiting list in the United States", section on 'Cardiovascular testing'</a> and  <a class="medical medical_review" href="/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Cardiovascular disease'</a>.)</p><p>Echocardiography is the test of choice to assess ventricular systolic and diastolic dysfunction and LVH as it is widely available, noninvasive, and provides information on atrial and ventricular volumes, LV mass, biventricular systolic and diastolic function, valve function, and pulmonary pressures. LVH is defined as an LV mass index ≥134 and ≥110 g/m<sup>2</sup> body surface area in males and females, respectively.</p><p>If LV systolic function cannot be adequately assessed by echocardiography, alternative methods include radionuclide ventriculography, CMR imaging (for which no exogenous contrast is required for assessment of LV structure and function), cardiac computed tomography (which requires iodinated contrast), and invasive ventriculography (generally performed only if there is a concurrent indication for cardiac catheterization such as an indication for coronary angiography). (See  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a>.)</p><p>In addition to the above described screening, patients should undergo diagnostic evaluation if they develop symptoms or signs of HF, recurrent hypotension with hemodialysis, or a cardiac event [<a href="#rid44">44</a>]. Diagnostic evaluation of patients with symptoms and signs of HF is discussed below. (See <a class="local">'Diagnosis of heart failure'</a> below.)</p><p class="headingAnchor" id="H3297164078"><span class="h2">For arrhythmias</span><span class="headingEndMark"> — </span>Screening for atrial and ventricular arrhythmias in patients on dialysis is generally limited to obtaining a 12-lead ECG at the time of initiation of dialysis and annually. In addition, patients with symptoms and signs of arrhythmias should undergo evaluation as discussed separately. (See  <a class="medical medical_review" href="/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician"</a> and  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/116601.html" rel="external">"Wide QRS complex tachycardias: Causes, epidemiology, and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis"</a>.)</p><p class="headingAnchor" id="H1472637009"><span class="h3">For atrial fibrillation</span><span class="headingEndMark"> — </span>The clinical manifestations and diagnosis of atrial fibrillation are discussed separately. (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H1184549988"><span class="h3">For ventricular arrhythmias</span><span class="headingEndMark"> — </span>The clinical manifestations and diagnosis of ventricular arrhythmias and the risk of sudden cardiac arrest in patients with ESKD are discussed separately. (See  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis"</a> and  <a class="medical medical_review" href="/d/html/116601.html" rel="external">"Wide QRS complex tachycardias: Causes, epidemiology, and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/1922.html" rel="external">"Evaluation of sudden cardiac arrest and sudden cardiac death in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS OF HEART FAILURE</span></p><p class="headingAnchor" id="H1492051965"><span class="h2">Causes and risk factors</span><span class="headingEndMark"> — </span>Factors contributing to HF in the patient on dialysis include fluid overload, LV diastolic dysfunction, LV systolic dysfunction, and valvular heart disease (eg, aortic stenosis). A high-output state caused by shunting through hemodialysis arteriovenous access can also precipitate HF, particularly in patients with underlying ventricular dysfunction [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a> and  <a class="medical medical_review" href="/d/html/113041.html" rel="external">"Clinical manifestations, diagnosis, and management of high-output heart failure"</a>.)</p><p>Risk factors for new-onset HF in end-stage kidney disease (ESKD) patients are similar to the general population and include hypertension, older age, anemia, ischemic heart disease, and baseline systolic dysfunction [<a href="#rid13">13,40</a>]. The prevalence of atheromatous disease in ESKD is high, and this may, in part, be due to the clustering of risk factors and the direct result of kidney function impairment. (See  <a class="medical medical_review" href="/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)"</a> and  <a class="medical medical_review" href="/d/html/1848.html" rel="external">"Hypertension in patients on dialysis"</a>.)</p><p>The pathophysiology of heart disease in patients on dialysis is discussed above. (See <a class="local">'Pathophysiology'</a> above.)</p><p class="headingAnchor" id="H4219055757"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Symptoms and signs of HF in patients with ESKD are the same as those observed generally. Symptoms include dyspnea, orthopnea, fatigue, and weakness. Signs include elevated jugular venous pressure, an S3 gallop, rales, and peripheral edema. ECG findings (such as LV hypertrophy [LVH] and changes consistent with myocardial infarction or ischemia) are not specific for HF but may suggest a cause of HF. The chest radiograph findings of cardiomegaly, cephalization of pulmonary vessels, Kerley B-lines, and alveolar edema strongly suggest HF but have limited sensitivity. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1587957369"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The clinical syndrome of HF is diagnosed in patients with ESKD based upon identification of a combination of symptoms, signs, and test findings. The evaluation is the same as that for HF generally except that we do not use natriuretic peptides to diagnose HF in patients with ESKD. Similar to the general population, there is a high incidence of HF with preserved ejection fraction (HFpEF). (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Evaluation'</a>.)</p><p>In addition, signs of diastolic dysfunction are common among asymptomatic patients on dialysis; diastolic dysfunction is a predictor of adverse cardiovascular outcomes including development of HF [<a href="#rid51">51,52</a>]. Some sedentary patients with asymptomatic diastolic dysfunction may develop symptoms and signs of HFpEF with stress.</p><p>The role of cardiac tests in the diagnostic evaluation of HF is discussed separately. Since HF is a clinical diagnosis, echocardiography is not used to exclude HF but to identify findings consistent with HF and potential causes of HF (eg, LV systolic dysfunction, LV diastolic dysfunction, and valve dysfunction). Cardiac catheterization is not generally required to diagnose HF, but right heart catheterization may be helpful in selected cases to assess intracardiac pressures and volume status, which may be challenging to assess noninvasively in patients on dialysis.</p><p>The use of serial change (either a rise or fall) rather than a static level of cardiac troponin I or T to diagnosis acute myocardial infarction (AMI) in patients with chronic kidney disease (CKD) is discussed separately. (See  <a class="medical medical_review" href="/d/html/1920.html" rel="external">"Cardiac troponins in patients with kidney disease"</a>.)</p><p class="headingAnchor" id="H476811348"><span class="h3">Identification of the type of heart failure</span><span class="headingEndMark"> — </span>While most patients with HF (whether HF with reduced ejection fraction [HFrEF], LVEF ≤40 percent; HFpEF, LVEF ≥50 percent; or HF with mid-range ejection fraction [HFmrEF], LVEF 41 to 49 percent) have low or normal cardiac output accompanied by elevated systemic vascular resistance.</p><p>A minority of patients with HF present with a high-output state with low systemic vascular resistance. High-output HF should be suspected in patients with predisposing conditions, particularly patients with arteriovenous access for hemodialysis. Patients with high-output HF frequently have concurrent cardiac disease with impaired systolic and/or diastolic function. Diagnosis of high-output HF is discussed separately. (See  <a class="medical medical_review" href="/d/html/113041.html" rel="external">"Clinical manifestations, diagnosis, and management of high-output heart failure"</a> and  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a>.)</p><p class="headingAnchor" id="H2510550387"><span class="h3">Limited utility of natriuretic peptides</span><span class="headingEndMark"> — </span>Neither B-type natriuretic peptide (BNP) nor the amino terminal fragment of the proBNP molecule (NT-proBNP) is sufficiently accurate for diagnosing HF in patients with ESKD. Plasma BNP and NT-proBNP concentrations are elevated in patients with renal failure due to reduced clearance, so thresholds for diagnosis of HF in patients on dialysis have not been established. (See  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a>.)</p><p>This contrasts with the utility of BNP and NT-proBNP in identifying patients with asymptomatic or symptomatic LV dysfunction among patients with normal renal function or mild to moderate CKD (defined as an estimated glomerular filtration rate [eGFR] &gt;30 mL/min/1.73 m<sup>2</sup>). (See  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure", section on 'Renal failure'</a>.)</p><p>Both BNP and NT-proBNP can provide prognostic information with respect to all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with ESKD, although we generally do not use either for this purpose. In a meta-analysis combining 23 studies and nearly 8000 ESKD patients, an elevated natriuretic peptide level was associated with a 3.85 higher odds ratio for all-cause mortality (95% CI 3.11-4.75) [<a href="#rid53">53</a>]. The odds ratio for cardiovascular death was 4.05 (95% CI 2.53-6.84), but with high heterogeneity, when evaluating 10 studies with 6396 ESKD subjects.</p><p class="headingAnchor" id="H1277600323"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H1437836"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular disease is an important cause of morbidity and mortality in patients with end-stage kidney disease (ESKD). With declining renal function, there is a progressive shift from ischemic to nonischemic etiologies of cardiac death, particularly sudden death in the absence of evidence of an acute myocardial infarction (AMI). (See <a class="local">'Prevalence and prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular hypertrophy (LVH) is a major risk factor for cardiovascular morbidity and mortality in patients on dialysis. Major risk factors for LVH include hypertension (particularly systolic blood pressure) and increasing age; chronic volume overload, anemia, and increased cardiac index may be contributing factors. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure (HF) is common among patients on dialysis and predicts early mortality. Risk factors for HF include hypertension, older age, anemia, ischemic heart disease, and baseline systolic dysfunction. (See <a class="local">'Pathophysiology'</a> above and <a class="local">'Causes and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the high burden of heart disease among patients on dialysis, we suggest that patients receiving maintenance dialysis undergo screening for heart disease including assessment of any symptoms and signs of heart disease, screening for cardiovascular risk factors, a 12-lead ECG (at initiation of dialysis and annually), and a Doppler transthoracic echocardiogram (once the patient is at dry weight within the first one to three months after initiation of dialysis and repeated every three years). In each patient on dialysis, this screening is performed to determine the presence of and need for additional testing for coronary heart disease, valvular heart disease, ventricular dysfunction, and arrhythmia. Screening of asymptomatic patients is performed in addition to standard diagnostic evaluation of patients with symptoms and signs of heart disease. (See <a class="local">'Approach to screening and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional testing to screen for coronary heart disease is performed in selected patients on dialysis including those with LV ejection fraction (LVEF) &lt;40 percent as well as in selected potential renal transplant recipients. Screening is performed by noninvasive stress imaging (nuclear or echocardiographic) and/or coronary angiography. Additional criteria for stress testing and considerations in choosing a screening test are discussed separately. (See <a class="local">'For coronary heart disease'</a> above and  <a class="medical medical_review" href="/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Coronary artery disease'</a> and  <a class="medical medical_review" href="/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)", section on 'Evaluation at dialysis initiation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valvular heart disease should be assessed during the screening clinical evaluation and Doppler echocardiography. For asymptomatic patients on dialysis found to have valvular heart disease, recommendations for monitoring are similar to those for the general population except for greater frequency of follow-up for aortic stenosis. (See <a class="local">'For valvular heart disease'</a> above and  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease"</a> and  <a class="medical medical_review" href="/d/html/8117.html" rel="external">"Medical management of asymptomatic aortic stenosis in adults", section on 'Serial evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ventricular dysfunction (eg, LV diastolic and/or systolic dysfunction) and LV remodeling (eg, LVH) should be assessed during the screening clinical evaluation and echocardiography. (See <a class="local">'For ventricular dysfunction'</a> above and  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for atrial and ventricular arrhythmias in patients on dialysis is generally limited to obtaining a 12-lead electrocardiogram at the time of initiation of dialysis and annually. (See  <a class="medical medical_review" href="/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician"</a> and  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/116601.html" rel="external">"Wide QRS complex tachycardias: Causes, epidemiology, and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical syndrome of HF is diagnosed in patients with ESKD based upon identification of a combination of symptoms, signs, and test findings. The evaluation as the same as that for HF generally except that we do not use natriuretic peptides to diagnose HF in patients with ESKD. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure", section on 'Renal failure'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wang X, Shapiro JI. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol 2019; 15:159.</a></li><li><a class="nounderline abstract_t">Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005; 67:217.</a></li><li><a class="nounderline abstract_t">Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12:1079.</a></li><li><a class="nounderline abstract_t">Park M, Hsu CY, Li Y, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012; 23:1725.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11:1277.</a></li><li><a class="nounderline abstract_t">Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19:1829.</a></li><li><a class="nounderline abstract_t">Karavelioğlu Y, Özkurt S, Karapinar H, et al. Evaluation of left ventricular diastolic function in nonhypertensive nondiabetic hemodialysis patients. Blood Press Monit 2013; 18:239.</a></li><li><a class="nounderline abstract_t">Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12:2768.</a></li><li><a class="nounderline abstract_t">de Roij van Zuijdewijn CL, Hansildaar R, Bots ML, et al. Eccentric Left Ventricular Hypertrophy and Sudden Death in Patients with End-Stage Kidney Disease. Am J Nephrol 2015; 42:126.</a></li><li><a class="nounderline abstract_t">Jukema JW, Timal RJ, Rotmans JI, et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation 2019; 139:2628.</a></li><li><a class="nounderline abstract_t">Said K, Hassan M, Baligh E, et al. Ventricular function in patients with end-stage renal disease starting dialysis therapy: a tissue Doppler imaging study. Echocardiography 2012; 29:1054.</a></li><li><a class="nounderline abstract_t">Hickson LJ, Negrotto SM, Onuigbo M, et al. Echocardiography Criteria for Structural Heart Disease in Patients With End-Stage Renal Disease Initiating Hemodialysis. J Am Coll Cardiol 2016; 67:1173.</a></li><li><a class="nounderline abstract_t">House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:1304.</a></li><li><a class="nounderline abstract_t">Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4:1486.</a></li><li><a class="nounderline abstract_t">Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. Semin Dial 2004; 17:299.</a></li><li><a class="nounderline abstract_t">Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393.</a></li><li><a class="nounderline abstract_t">Edwards NC, Moody WE, Chue CD, et al. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging 2014; 7:703.</a></li><li><a class="nounderline abstract_t">Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69:1839.</a></li><li><a class="nounderline abstract_t">Schietinger BJ, Brammer GM, Wang H, et al. Patterns of late gadolinium enhancement in chronic hemodialysis patients. JACC Cardiovasc Imaging 2008; 1:450.</a></li><li><a class="nounderline abstract_t">Aoki J, Ikari Y, Nakajima H, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005; 67:333.</a></li><li><a class="nounderline abstract_t">Patel RK, Mark PB, Macnaught G, et al. Altered relative concentrations of high-energy phosphates in patients with uraemic cardiomyopathy measured by magnetic resonance spectroscopy. Nephrol Dial Transplant 2012; 27:2446.</a></li><li><a class="nounderline abstract_t">Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4:914.</a></li><li><a class="nounderline abstract_t">Assa S, Hummel YM, Voors AA, et al. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 2012; 7:1615.</a></li><li><a class="nounderline abstract_t">Hothi DK, Rees L, Marek J, et al. Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 2009; 4:790.</a></li><li><a class="nounderline abstract_t">Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009; 4:1925.</a></li><li><a class="nounderline abstract_t">Di Marco GS, Hausberg M, Hillebrand U, et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 2008; 294:F1381.</a></li><li><a class="nounderline abstract_t">Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16:1788.</a></li><li><a class="nounderline abstract_t">Tumur Z, Niwa T. Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 2009; 29:551.</a></li><li><a class="nounderline abstract_t">Yang K, Xu X, Nie L, et al. Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway. Toxicol Lett 2015; 234:110.</a></li><li><a class="nounderline abstract_t">Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev 2010; 6:82.</a></li><li><a class="nounderline abstract_t">Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.</a></li><li><a class="nounderline abstract_t">Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551.</a></li><li><a class="nounderline abstract_t">Cao XS, Chen J, Zou JZ, et al. Association of indoxyl sulfate with heart failure among patients on hemodialysis. Clin J Am Soc Nephrol 2015; 10:111.</a></li><li class="breakAll">United States Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institute of Health, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD 2013.</li><li><a class="nounderline abstract_t">Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296.</a></li><li class="breakAll">United States Renal Data System. 2017 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2017.</li><li class="breakAll">USRDS 2020 Report, volume 2. Atlas ESRD, Chapter 8: Cardiovascular Disease in Patients with ESRD. https://adr.usrds.org/2020/end-stage-renal-disease/8-cardiovascular-disease-in-patients-with-esrd (Accessed on October 10, 2021).</li><li><a class="nounderline abstract_t">Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation 2021; 143:e254.</a></li><li><a class="nounderline abstract_t">Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41:1267.</a></li><li><a class="nounderline abstract_t">Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47:884.</a></li><li><a class="nounderline abstract_t">Zoccali C, Benedetto FA, Tripepi G, et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol 2006; 17:1460.</a></li><li><a class="nounderline abstract_t">Postorino M, Marino C, Tripepi G, et al. Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant 2007; 22:1377.</a></li><li><a class="nounderline abstract_t">Banerjee D, Ma JZ, Collins AJ, Herzog CA. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007; 2:1186.</a></li><li><a class="nounderline abstract_t">K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.</a></li><li><a class="nounderline abstract_t">Sarnak MJ, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 74:1823.</a></li><li><a class="nounderline abstract_t">Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation 2020; 104:S11.</a></li><li><a class="nounderline abstract_t">Eckardt KU, Bansal N, Coresh J, et al. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2018; 93:1281.</a></li><li><a class="nounderline abstract_t">Chang ST, Chen CL, Chen CC, Hung KC. Clinical events occurrence and the changes of quality of life in chronic haemodialysis patients with dry weight determined by echocardiographic method. Int J Clin Pract 2004; 58:1101.</a></li><li><a class="nounderline abstract_t">Kayatas M, Ozdemir N, Muderrisoglu H, et al. Comparison of the non-invasive methods estimating dry weight in hemodialysis patients. Ren Fail 2006; 28:217.</a></li><li><a class="nounderline abstract_t">Reddy YNV, Obokata M, Dean PG, et al. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J 2017; 38:1913.</a></li><li><a class="nounderline abstract_t">Barberato SH, Bucharles SG, Sousa AM, et al. [Prevalence and prognostic impact of diastolic dysfunction in patients with chronic kidney disease on hemodialysis]. Arq Bras Cardiol 2010; 94:457.</a></li><li><a class="nounderline abstract_t">Takase H, Dohi Y, Toriyama T, et al. B-type natriuretic peptide levels and cardiovascular risk in patients with diastolic dysfunction on chronic haemodialysis: cross-sectional and observational studies. Nephrol Dial Transplant 2011; 26:683.</a></li><li><a class="nounderline abstract_t">Cheng YJ, Yao FJ, Liu LJ, et al. B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis. PLoS One 2013; 8:e79302.</a></li></ol></div><div id="topicVersionRevision">Topic 1846 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30664681" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evolving concepts in the pathogenesis of uraemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610245" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Electrocardiographic abnormalities and uremic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316868" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Left ventricular hypertrophy in the renal patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935481" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Associations between kidney function and subclinical cardiac abnormalities in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8672023" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcome and risk factors for left ventricular disorders in chronic uraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128888" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013617" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation of left ventricular diastolic function in nonhypertensive nondiabetic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11729247" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26382055" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eccentric Left Ventricular Hypertrophy and Sudden Death in Patients with End-Stage Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882234" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672255" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ventricular function in patients with end-stage renal disease starting dialysis therapy: a tissue Doppler imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26965538" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Echocardiography Criteria for Structural Heart Disease in Patients With End-Stage Renal Disease Initiating Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053387" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8161730" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250922" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiac consequences of hypertension in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985788" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : FGF23 induces left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034920" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508657" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356466" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Patterns of late gadolinium enhancement in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610259" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241795" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Altered relative concentrations of high-energy phosphates in patients with uraemic cardiomyopathy measured by magnetic resonance spectroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357245" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hemodialysis-induced cardiac injury: determinants and associated outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22822014" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339406" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808220" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385273" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased inorganic phosphate induces human endothelial cell apoptosis in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814832" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129694" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25703824" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532773" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784625" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696217" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25332316" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of indoxyl sulfate with heart failure among patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25332316" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Association of indoxyl sulfate with heart failure among patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385656" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385656" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385656" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33501848" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12776280" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Heart failure as a cause for hospitalization in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752588" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597683" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276995" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prognostic value of the New York Heart Association classification in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942779" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806502" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31582143" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32301874" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29656903" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15646404" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical events occurrence and the changes of quality of life in chronic haemodialysis patients with dry weight determined by echocardiographic method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16703793" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparison of the non-invasive methods estimating dry weight in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329100" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20339814" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : [Prevalence and prognostic impact of diastolic dysfunction in patients with chronic kidney disease on hemodialysis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624772" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : B-type natriuretic peptide levels and cardiovascular risk in patients with diastolic dysfunction on chronic haemodialysis: cross-sectional and observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24236118" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
